Randomized Trialhigh evidence
Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial.
Nature medicine·August 29, 2026·PMID 42668287
Why it mattersSelecting antithrombotic therapy for patients with both atrial fibrillation and acute coronary syndrome requires balancing bleeding and ischemic risks. This trial directly addresses whether using more potent P2Y12 inhibitors with DOACs improves outcomes, a question relevant to cardiologists managing these complex patients.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled